MIRA Pharmaceuticals (NASDAQ:MIRA) Releases Quarterly Earnings Results, Misses Expectations By $1.07 EPS

MIRA Pharmaceuticals (NASDAQ:MIRA) announced its quarterly earnings results on Tuesday. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($1.07), Zacks reports.

MIRA Pharmaceuticals Trading Down 6.3%

Shares of NASDAQ MIRA traded down $0.09 during mid-day trading on Thursday, hitting $1.34. The company had a trading volume of 411,646 shares, compared to its average volume of 1,713,843. MIRA Pharmaceuticals has a 1 year low of $0.73 and a 1 year high of $2.45. The company has a market capitalization of $25.55 million, a price-to-earnings ratio of -2.78 and a beta of 1.72. The stock’s 50-day moving average price is $1.43 and its 200-day moving average price is $1.39.

Analyst Upgrades and Downgrades

MIRA has been the topic of several analyst reports. Wall Street Zen upgraded shares of MIRA Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, October 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a research report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Institutional Trading of MIRA Pharmaceuticals

A hedge fund recently bought a new stake in MIRA Pharmaceuticals stock. XTX Topco Ltd purchased a new stake in shares of MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) in the second quarter, according to its most recent 13F filing with the SEC. The fund purchased 21,873 shares of the company’s stock, valued at approximately $26,000. XTX Topco Ltd owned approximately 0.13% of MIRA Pharmaceuticals at the end of the most recent reporting period. 35.16% of the stock is owned by institutional investors and hedge funds.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.